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The clinical usefulness of antineutrophil cytoplasmic antibodies (ANCAs) in the monitoring of patients
treated for small vessel vasculitis is debated. A capture enzyme-linked immunosorbent assay (ELISA) based on
anti-proteinase 3 (anti-PR3) monoclonal antibody 4A3 has previously been proven to be superior to indirect
immunofluorescence (IIF) and standard ELISA for the diagnosis of vasculitis. The present study compared the
effectiveness of the capture ELISA for the detection of disease relapse. Samples from patients with relapses and
remissions (relapse and remission samples, respectively) were identified through the database of the Glomer-
ular Disease Collaborate Network. Twenty-one relapse samples and 49 remission samples were analyzed by the
capture PR3-ANCA ELISA from Wieslab AB, the standard PR3-ANCA ELISA from Inova, and IIF. A Medline
search was performed to identify published data on ANCA status at relapse. The capture ELISA was positive
for 21 instances of relapses in 14 patients, while the standard ELISA and IIF each failed to detect 2 relapses
(P was not significant). By using a higher cutoff value, the capture ELISA correctly categorized 84% of the
remission samples and 81% of the relapse samples. Similar degrees of discrimination could be achieved by IIF
but not by the standard ELISA. In previously published series, the median proportions of patients positive at
relapse were 100% by IIF (range, 75 to 100%) and 86% by standard ELISA (range, 38 to 100%). The
corresponding values for a rise that accompanied or preceded a relapse were 75% (range, 20 to 100%) for IIF
and 50% (range, 25 to 81%) for ELISA. The capture PR3-ANCA ELISA is a sensitive tool for the detection of
relapses. Larger studies are needed to detect differences between methods. Negative results by tests for ANCAs
are rare during relapses.
Measurement of antineutrophil cytoplasmic antibodies
(ANCAs) is an established tool for the diagnostic workup of
patients with small vessel vasculitis. However, different views
concerning the usefulness of serial ANCA measurements for
the monitoring of patients prevail. In the original report link-
ing ANCAs to Wegener’s granulomatosis in 1985, it was stated
that ANCA titers are related to disease activity (29). Later it
was claimed that treatments based on ANCA titers were more
beneficial than treatments based only on clinical signs and
symptoms (5). This notion has been challenged. For instance,
a report from the National Institutes of Health found that
changes in ANCA titers were poorly correlated with disease
activity (7, 15).
On the basis of the antigen specificities of the autoantibod-
ies, ANCAs are divided into two major categories, proteinase
3 (PR3) ANCAs (PR3-ANCAs) and myeloperoxidase ANCAs.
ANCAs can be detected either by indirect immunofluores-
cence (IIF) with normal neutrophils or by immunochemical
methods, such as enzyme-linked immunosorbent assay
(ELISA). Different methods do not yield identical results, and
the correlations between the titers obtained by different assays
are especially poor (30). One basis for these discrepancies is
the presence of antigenic molecules other than PR3 and my-
eloperoxidase in the specimen used for the assay. For instance,
antibodies to bactericidal/permeability increasing protein can
give rise to a classic ANCA (C-ANCA) pattern that is indis-
tinguishable from the PR3 pattern. Discrepancies are also due
to differences in the way in which the antigens are presented in
different assays. Autoantigenic epitopes may be masked or
enhanced by fixation and coating. During fixation for IIF, in-
teractions with other granule constituents may mask epitopes
and lower the sensitivity (24). During coating for standard
ELISA, denaturation may alter the antigenicities of conforma-
tional epitopes on PR3. A capture assay reduces the problem
with coating by immobilizing the antigen with a previously
coated monoclonal antibody. However, this introduces the risk
that the monoclonal antibody is directed to the same epitope
region as the autoantibodies in the test sample. Under such
circumstances PR3 will be unavailable for the autoantibodies
in the test sample, yielding a false-negative result. Circulating
immune complexes containing PR3 and anti-PR3 may also be
detected by a capture assay but not by a standard ELISA.
After having defined three major nonoverlapping epitope
regions on the PR3 molecule, a capture ELISA was developed
(25). This assay has previously been shown to exhibit a higher
degree of sensitivity and a similar degree of specificity for the
detection of systemic vasculitis compared with the sensitivities
and specificities of IIF and standard direct ELISA (2). In the
study described in this report we studied the ability of this
capture assay to detect relapses among patients with PR3-
ANCA-associated small vessel vasculitis compared with those
of a standard PR3 ELISA and IIF. We also compared our
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results with those of previously published investigations con-
cerning the use of ANCAs for the detection of relapses in
patients with vasculitis.
MATERIALS AND METHODS
Patients and sera. Patients with biopsy-proven PR3-ANCA-associated small
vessel vasculitis with renal involvement were detected through the Glomerular
Disease Collaborate Network database at the University of North Carolina at
Chapel Hill. This cohort has been monitored prospectively since the day of
biopsy, and remissions and relapses have been recorded as published previously
(19). In short, a relapse was defined as the occurrence of one of the following: (i)
a rapid rise in serum creatinine levels accompanied by active urine sediment, (ii)
the detection of necrosis or crescent formation by renal biopsy or the identifi-
cation of necrotizing vasculitis in other tissue, (iii) pulmonary hemorrhage or
expanding nodules, (iv) the observation of active vasculitis in the gut by endos-
copy, (v) iritis or uveitis, or (vi) new mononeuritis multiplex. The results of
ANCA testing were not included in the criteria used to define relapses and
remissions.
Serum samples were retrieved from the serum bank of the Nephropathology
Laboratory at the University of North Carolina at Chapel Hill. Healthy blood
donors were used as negative controls. From each instance of relapse noted in
the database, a serum sample was retrieved from the serum bank, when such a
sample was available. Serum samples were classified as “relapse samples” if they
were drawn within a period of 30 days before and 60 days after the date of relapse
noted in the database. If several serum samples were available from the same
relapse episode, the one closest to the date of relapse was included in the study.
Most of the samples included were drawn within 1 week of the recorded relapse.
Samples were classified as “remission samples” if at least 3 months had passed
since the last flare of vasculitis and if there was a documented disease-free period
of at least 3 months after the sample was drawn. For each patient, no more than
six remission samples drawn at least 1 month apart were included in the study.
The study was performed in accordance with local ethical guidelines.
Capture ELISA. The capture PR3 ELISA kit was a gift from Wieslab AB
(Lund, Sweden) and was used according to the instructions of the manufacturer.
In short, purified PR3 at a concentration of 1 g/ml in phosphate-buffered saline
was added to microtiter plates precoated with monoclonal antibody 4A3, and the
plates were incubated at room temperature for 60 min. Sera diluted 1:80 in
phosphate-buffered saline with 0.1% bovine serum albumin and 0.05% Tween 20
were incubated in duplicate wells for 60 min at room temperature, and after
washing of the plates, bound immunoglobulin G was detected with alkaline
phosphatase-conjugated anti-human immunoglobulin G. To exclude nonspecific
binding and rheumatoid factor binding, a control plate precoated with an unre-
lated monoclonal antibody of the same mouse immunoglobulin subclass was run
in parallel with the plate with monoclonal antibody 4A3. For each well, the
absorbance values for this plate were subtracted from the absorbance values for
the anti-PR3-coated plate. The results of the capture PR3 ELISA were catego-
rized as negative if the result was 20 ELISA units and positive if the result was
20 ELISA units, on the basis of the mean value for healthy blood donors  3
standard deviations. The interassay variability was determined to be 7%, while
the intra-assay variability by comparison of the results for individual wells was
8%. A significant increase was defined as a 50% or greater rise in the number of
ELISA units. However, increases had to be at least 20 ELISA units in absolute
numbers (the same value as the limit for a positive result) to be considered
significant. The definition for a significant increase was made arbitrarily before
any tests were performed.
Standard ELISA. A standard commercial PR3-ANCA ELISA kit (Inova) was
used with modification. Instead of the secondary antibody supplied with the kit,
alkaline phosphatase-conjugated anti-human gamma chain from Inova was used.
Extensive evaluation of this assay system has shown that it has a sensitivity and
a specificity comparable to or better than those of multiple commercial kits (17).
Standard ELISA results were categorized as negative if the result was 15
ELISA units and positive if the result was 15 ELISA units. A significant
increase was defined as a rise in the number of ELISA units of 50% or more, with
a minimum increase of 15 units required (the same value as the limit for a
positive result).
IIF. IIF was performed with ethanol-fixed granulocytes in accordance with
internationally accepted guidelines (23). One experienced investigator (J.C.J.)
analyzed all samples. The starting dilution was 1:20, and all samples were titrated
until a negative finding was obtained. An increase of two titration steps or more
was defined as a significant increase.
Literature search. The following search terms were entered into the Medline
database: “ANCA and follow-up,” “ANCA and serial,” “ANCA and outcome,”
“ANCA and relapse,” and “ACPA” (anticytoplasmic autoantibodies). All arti-
cles in the English language for which the abstract suggested that the article
contained systematic evaluation of C-ANCA or PR3-ANCA values during dis-
ease relapses were selected for extraction of data. Single case reports, data
concerning patients with transplants, and data obtained by methods that did not
distinguish between C-ANCAs and perinuclear ANCAs were not included. Re-
ports in which the results of ANCA testing were included in the definition of
relapse or remission were also excluded.
RESULTS
Relapses. Samples from 21 relapses in 14 individuals (11
men and 3 women) were analyzed by the capture ELISA, the
standard PR3 ELISA, and IIF. The results are presented in
Fig. 1. The median age of the patients at the time of the first
relapse was 50 years (age range, 40 to 82 years). All 21 relapses
were identified by the capture ELISA, while the standard
ELISA and IIF each failed to recognize 2 relapses (not in the
same patients). Even the lowest value detected by the capture
ELISA during a relapse (69 ELISA units) was more than a
factor of 3 above the normal range.
For 13 of the relapse episodes, the value for the relapse
sample could be compared with the values for samples drawn
during a disease-free interval prior to the relapse. A significant
increase was documented for all 13 episodes by the capture
ELISA, while significant increases were seen for 10 episodes
each by IIF and the standard ELISA (Table 1). Only one of the
relapses went undetected by both IIF and the standard ELISA,
while four relapses were detected by one method but not the
other.
Remission. A total of 49 samples from 20 patients in remis-
sion were allocated for this study. Among these 49 samples, 17
samples were from 10 patients who had never experienced a
relapse during follow-up. Thirty-two samples were from 10
patients who subsequently developed at least one relapse.
Many patients were ELISA positive during remission, but the
titers were usually lower than the titers measured during re-
lapse (Fig. 1). Among the 49 samples taken during remission,
14 were negative by capture ELISA, 26 were negative by IIF,
and 7 were negative by standard ELISA. The best discrimina-
tion between relapse samples and remission samples for the
capture ELISA was achieved by using 100 ELISA units as the
upper limit. With this cutoff, 41 of 49 (84%) of the remission
samples had values below the cutoff and 17 of 21 (81%) of the
relapse samples had values above the cutoff. A similar result
was obtained by IIF with a value of 1:80 as a limit (41 of 49
remission samples and 19 of 21 relapse samples had values
above and below the cutoff, respectively). The relationship
between the capture ELISA results and the IIF results is shown
in Fig. 2. When the capture ELISA results were between 50
and 100 ELISA units, evaluation by capture ELISA in combi-
nation with IIF seemed to provide additional information, with
no relapses observed among patients with 100 ELISA units
by the capture assay in conjunction with a value of 1:80 by
IIF. For the standard ELISA, no titer provided a clear distinc-
tion between relapses and remissions. Use of 40 ELISA units
as the cutoff point for the standard ELISA resulted in the titers
for 86% (18 of 21) of the relapse samples being above the
cutoff but the titers for only 57% (28 of 49) of the remission
samples titers being below the cutoff. The better discrimination
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between remission and relapse by IIF and capture ELISA than
by the standard ELISA is shown in Fig. 1.
Review of the literature. Twenty articles were found to con-
tain systematic data concerning ANCA measurements during
follow-up. The data are summarized in Table 2 together with
the data from the present study. Approximately 250 relapses
have been investigated by IIF. Since relapses are defined in
many different ways and the technique for IIF was not stan-
dardized, an arithmetic mean value for samples with positive
results was not calculated. The median value of the results
across all studies, including the present study, was 100%
(range, 75 to 100%). Fewer data concerning the standard ELISA
were found in the literature, with eight articles reporting the
results of the standard ELISA for approximately 125 relapses
being found. The median proportion of positive results for the
detection of ANCAs by the standard ELISA at clinical relapse
was 86% (range, 38 to 100%). Most of the articles also sum-
marized data regarding increases in ANCA titers that either
preceded or accompanied relapses. The median proportions of
rises in ANCA titers before or in conjunction with a relapse
were 75% for IIF (range, 20 to 100%) and 50% for the stan-
dard ELISA (range, 25 to 81%).
A smaller number of studies also included data on the oc-
currence of increases in ANCA titer in the absence of clinical
FIG. 1. Values of ANCA determinations for 49 remission samples from 20 patients and 21 relapse samples from 14 patients analyzed by capture
PR3-ANCA ELISA (A), standard PR3-ANCA ELISA (B), and IIF (C). Horizontal bars indicate median levels, and boxes indicate the first and
third quartiles. The discrimination between relapse and remission seems to be better by the IIF and capture techniques than by the standard
ELISA.




















M/82 E, L, K Neg Neg 2c 47 24 163
M/51 E,  Neg 1:80 53 82 76 211
M/49 E, K 1:20 1:320d 114 184d 15 78d
M/65 L, K,  Neg 1:320 5 74 17 398
F/46 E, K,  Neg 1:160 22 57 17 74
—/46 E 1:20 1:160 16 41 43 102
—/47 E 1:40 1:160 4 14 46 76
M/68 L 1:320 Neg 80 125 3 233
F/72 K Neg 1:1,280 2 157 16 537
M/72 K,  Neg 1:160d 17 123d 3 358d
—/76 K,  1:160 1:320 156 151 173 383
F/40 L Neg 1:320 5 72 10 71
M/41 EI 1:20 1:160 28 22 77 210
a M, male; F, female; —, multiple relapses from the same patient, i.e., the patient for whom data is presented in the preceding row.
b Organ system involvement at time of relapse: E, upper respiratory tract; L, lower respiratory tract; K, kidney; , other organ systems.
c Boldface indicates relapses accompanied by a significant increase.
d Data for the two patients from whom samples were drawn more than 2 weeks after the clinical diagnosis of relapse.
VOL. 10, 2003 PR3-ANCA MONITORING IN VASCULITIS 771
signs of disease activity (Table 2). The large discrepancies
between different studies make interpretation of this associa-
tion difficult. By IIF the proportion of significant increases in
titers not associated with relapse ranged from 0 to 86%, and by
ELISA this proportion ranged from 0 to 41%. Studies with
larger sample sizes tended to report a higher proportion of
false-positive tests (7).
DISCUSSION
This study shows that the capture ELISA for PR3-ANCAs
based on monoclonal antibody 4A3 is a sensitive tool for the
detection of relapses among patients with small vessel vascu-
litis. All instances of relapse included in this study yielded
positive results by the capture ELISA. When remission sam-
ples drawn prior to the relapse were available for comparison,
the capture assay detected significant changes in titer between
the states of remission and relapse. Most samples were positive
during remission, but the values were lower than those for
samples taken during a relapse. To distinguish between remis-
sion and relapse by the capture ELISA a limit of 50 or 100
ELISA units instead of 20 ELISA units, which is the current
borderline for positive versus negative results, must be used.
Still, there was considerable overlap, and a diagnosis of relapse
should not be made on the basis of a single result by the
capture assay. Instead, the best clinical use of the capture assay
is for the exclusion of relapses. If a patient has negative or
unchanging low values, the probability of active vasculitis is
likely to be low.
The performance of IIF was also good in this study. IIF was
negative for only 2 of 21 relapses, and increasing titers were
seen in 77% of the relapses. A larger study will be necessary to
conclude if the difference between the capture ELISA and IIF
is a consistent finding. A major disadvantage with the use of
IIF is that the outcome is dependent on the experience of the
person reading the slides. In this study we had optimal circum-
stances for evaluation by IIF, with all slides read by one inves-
tigator (J.C.J.) with a long track record assessing ANCA tests.
Other studies evaluating the clinical performance of IIF have
shown less favorable results (7).
Previously published results concerning ANCAs and re-
lapses have mainly been performed by IIF. Many of the studies
were performed before IIF for ANCAs was standardized. Our
results concerning IIF do not deviate from the results of oth-
ers, in which positive results were seen for 75 to 100% of the
published cases. Fewer data are available from studies that
have used the standard ELISA. These data are even more
difficult to compare because of the different methods applied.
However, the results indicate that the standard ELISA might
have a lower sensitivity for the detection of relapses than IIF
and the capture ELISA. This and two recent studies (1, 20) are
the only attempts that have been made to compare the abilities
of different ELISA methods to detect relapses. There are sub-
stantial differences in the results, especially between the Ger-
man study (20) and the present study. The reason for this
discrepancy is not clear, but one major difference between the
studies is how relapses were defined. In our study a minimum
of 3 months of remission must have elapsed for the two disease
periods to have been classified as separate relapses. Thus,
minor fluctuations in disease activity during an exacerbation
(which may render a change in the Birmingham vasculitis ac-
tivity score) were not listed as separate relapses.
In the present study the capture assay was better than the
standard ELISA method for discrimination between a relapse
and a remission. Most ANCAs are directed to conformational
epitopes on PR3. Breaking up of disulfide bonds or boiling of
the antigen diminishes or abolishes reactivity by Western blot-
ting analysis (30). The most probable explanation for the good
performance of the capture assay is that an epitope on PR3
that is sensitive and potentially relevant for disease activity is
better preserved or presented by this method. This is of theo-
retical interest concerning the role of ANCAs in the patho-
genesis of vasculitis. The ANCAs present during a remission
may have a lower capacity to elicit intracellular signaling
events. If so, it would also be possible, using recombinant
FIG. 2. Comparison between IIF titers and PR3-ANCA capture ELISA results from 49 remission samples (E) and 21 relapse samples (). The
capture assay detected all relapses, but a combination with an IIF titer above 1:80 decreases the likelihood of a false-positive result.
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technology, to construct molecules harboring only this relevant
epitope region and thus construct better assays in the future.
The small number of samples available from periods of
remission hampered this study. This prevents us from doing a
meaningful evaluation of the specificity of a rise in ANCA
titers for the detection of relapses. Other studies that have
focused on this issue claim that a rise in ANCA titer without a
relapse is relatively common (7). According to the previously
reported data, approximately half of all increases in ANCA
titers are associated with clinically significant relapses. Our
data cannot be used as an argument against this notion; in-
stead, they support the concept that the best use of ANCA
titers is for the exclusion of relapses.
In conclusion, the capture PR3 ELISA based on monoclonal
antibody 4A3 is a sensitive tool for the detection of relapses in
patients with systemic vasculitis. However, larger studies are
needed to conclude whether it is superior to other methods in
clinical practice.
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